FORT MYERS, Fla., February 17, 2026--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth ...

Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting ...